Fig. 3From: Multi-omics analysis uncovers clinical, immunological, and pharmacogenomic implications of cuproptosis in clear cell renal cell carcinomaConstruction and external verification of cuproptosis subtypes in ccRCC. A Consensus matrix depicts the consensus value k = 3 on a white to blue color scale based on the transcriptome profiling of cuproptosis genes in TCGA cohort. B Transcriptome profiling of cuproptosis genes in the three cuproptosis subtypes in TCGA cohort. Colors from blue to red display low to high expression. C PCA exhibits the discrimination of transcriptome profiling of cuproptosis genes among the three cuproptosis subtypes in TCGA cohort. D K-M curves for OS of the three cuproptosis subtypes in TCGA cohort. E Transcriptome profiling of up-regulated genes in each cuproptosis subtype in accordance with fold change > 1 and adjusted p < 0.05. F Transcriptome profiling of the template features in the cuproptosis subtypes in the E-MATB-1980 dataset. G Validation of OS difference among the three cuproptosis subtypes in the E-MATB-1980 cohort. H Validation of the discrimination of transcriptome profiling among the three cuproptosis subtypes via PCA in the E-MATB-1980 cohort. I Proportions of clinicopathological parameters in each cuproptosis subtype across TCGA ccRCC patientsBack to article page